as a precursor for rene's kit launch in the States (next month?), look at US analyst (upbeat) reaction to a new float: nlrs
today is trading day no 2 for nlrs on otc
it rose 25% on its debut yesterday
from the other RENE thread:
"[The method is] atypical, but it's not the first of its kind," said Steve Chizzik, whose New Jersey firm is handling Neuralstem's investor relations. "It's more expeditious."
At least one financial analyst expects a strong interest in shares traded today.
"This stock might trade substantially higher" than anticipated, financial analyst and former University of Virginia professor Michael A. Berry wrote on his investment Web site last week.
He based the prediction on the types of questions analysts asked of Neuralstem at a New York investor conference last month and the "significant potential" for the company to treat diseases such as Parkinson's.
Intercorp Excelle stock quotes
Intercorp Excelle stock charts
Follow this thread
